Synairgen, Pharmaxis Pair Up On LOXL2 Lung Disease Therapy

UK biotechnology company Synairgen plc is teaming up with Australian pharmaceutical company Pharmaxis Ltd to develop a new drug for idiopathic pulmonary fibrosis (IPF) which it hopes to pair up with a big pharma on later down the line.

UK biotechnology company Synairgen plc is teaming up with Australian pharmaceutical company Pharmaxis Ltd to develop a new drug for idiopathic pulmonary fibrosis (IPF) which it hopes to pair up with a big pharma on later down the line.

Synairgen and Pharmaxis are developing a selective inhibitor to the lysyl oxidase type 2 enzyme (LOXL2) from the latter firm's...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Alimentary/Metabolic

More from Therapeutic Category